Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (Levofloxacin and Amikacin)

Journal of the College of Physicians and Surgeons Pakistan

Volumn 25, Issue 5, 2015, Pages 337-341

  Mirza, Irfan Ali ^a   Khan, Farooq Ahmad ^b   Khan, Khursheed Ali ^c   Satti, Luqman ^d   Ghafoor, Tahir ^e   Fayyaz, Muhammad ^e  

^a Department of Microbiology PNS Shifa ^*  (Pakistan)

^b Rai Medical College   (Pakistan)

^c BAQAI MEDICAL UNIVERSITY   (Pakistan)

^d Malir National University of Medical Sciences   (Pakistan)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

Author keywords

Amikacin; Extensively drug resistant tuberculosis; Levofloxacin; Multi drug resistant tuberculosis; Pre extensively drug resistant tuberculosis

Indexed keywords

AMIKACIN; ISONIAZID; LEVOFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRE EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; YOUNG ADULT;

AMIKACIN; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; YOUNG ADULT;

EID: 84929662232     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Caminero JA, Torres A. Controversial topics in tuberculosis. Eur Respir J 2004; 24:895-6.
2. Grzybowski S, Enarson DA. Results in pulmonary tuberculosis patients under various treatment program conditions. Bull Int Union Tuberc 1978; 53:70-5.
3. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva: WHO; 2013.
4. World Health Organization. Global tuberculosis report 2013. Geneva: WHO; 2013.
5. World Health Organization. Roadmap to prevent and combat drug-resistant tuberculosis. Geneva: WHO; 2011.
6. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicentre laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second line drugs and newer antimicrobials. J Clin Microbiol 2006; 44:688-92.
7. Grace Lin SY, Desmond E, Siddiqi S. Multicentre evaluation of BACTEC MGIT 960 system for second line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009; 47:3630-4.
8. Abubakar I, Zignol M, Falzon D. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13:529-39.
9. Iqbal R, Shabbir I, Munir K, Chaudhry K, Qadeer E. The first and second line anti-TB drug resistance in Lahore. Pak J Med Res 2012; 51:1-4.
10. Bekotre B, Hanzedaraglu T, Baylon O, Ozyurt M, Ozkutuk N, Satana D, et al. Investigation of extensive drug resistance isolates in multidrug resistance tuberculosis isolates. Mikrobiyol Bul 2013; 47:59-70.
11. Porwal C, Kaushik A, Makkar N, Banawaliker JN, Hanif M, Singla R, et al. Incidence and risk factors for extensively drug resistant tuberculosis in Delhi region. PloS One 2013; 8: e25529.
12. Dheda K, Shean K, Zumla A. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375:1798-807.
13. Daniel O, Osman E, Oladimeji O, Dairo OG. Pre-extensive drug resistant tuberculosis (Pre-XDR-TB) among MDR-TB patients in Nigeria. Glo Adv Res J Microbiol 2013; 2:22-28.
14. Kozinska M, Brzostek, Krawiecka D, Rybczynska M, ZofiaZwolska Z, Ugustynowicz-Kopec E. MDR, pre-XDR and XDR drug resistant tuberculosis in Poland in 2000-2009. Pneumonol Alergol Pol 2011; 79:278-87.
15. Qi YC, Ma MJ, Li DJ, Chen MJ, Lu QB. Multidrug-resistant and extensively drug-resistant tuberculosis in multi-ethnic region, Xinjiang Uygur autonomous region, China. PLoS ONE 2012; 7: e32103.
16. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47:450-7.
17. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates:associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-65.
18. Butt ZA, Gilani AH, Nanan D, Sheikh AL, White F. Quality of pharmacies in Pakistan: a cross-sectional survey. Int J Qual Health Care 2007; 17:307-13.
19. Jabeen K, Nizamuddin S, Irfan S, Khan E, Malik F, Zafar A. Increasing trend of resistance to penicillin, tetracycline, and fluoroquinolone resistance in Neisseria gonorrhoeae from Pakistan (1992-2009). J Trop Med 2011; 960:501.
20. Hasan R, Zafar A, Abbas Z, Mehraj V, Malik F, Zaidi A. Antibiotic resistance among Salmonella enterica, Serovars typhi and paratyphi A in Pakistan (2001-2006). J Infect Develp Countr 2008; 2:289-94.
21. Adriaenssens N, Coenen S, Versporten A. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011; 66:47-56.
22. Khan JA, Malik A. Tuberculosis in Pakistan: are we losing the battle? J Pak Med Assoc 2003; 53:320-1.
23. Ali W, Naseem A, Hani M, Shahzad M, Ali FM. Status of health professionals awareness about resistant tuberculosis. Pak J Chest Med 2010; 16:4-8.
24. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, Li C. Comparison of gyrA gene mutations between laboratory-selected ofloxacinresistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008; 31:115-21.
25. Falzan D, Jaramillo E, Shunemann HJ. WHO guidelines for the programmatic management of drug resistant tuberculosis: 2011 update. Eur Resp J 2011; 38:516-28.